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The proteins  of the complement and coagulation  systems are major transducing 
mechanisms of plasma whereby small  initiating signals are amplified and translated 
into biological events. To date,  these systems have largely been studied  in isolation, 
although  interactions  between  them  may  be  expected.  Indeed  the  similarity  of 
structure  and mechanism of inhibition of Cls and Clr of the complement system (1) 
and Hageman factor, Factor XI, and prekallikrein of the intrinsic coagulation system 
(2)  are so similar as to raise the possibility of genetic reduplication  in their develop- 
ment.  Furthermore,  plasma kallikrein  has been shown to be capable of cleaving and 
activating both Cls and Clr (3). 
In the present study, we report the ability of kallikrein purified from rabbit plasma 
to generate chemotactic activity for rabbit neutrophils from rabbit C5. The study was 
prompted  by  previous  reports  that  human  kallikrein  was  directly  chemotactic  for 
human neutrophils  (4), an observation that we have not been able to confirm for the 
rabbit  system.  The results  suggest  the  existence  of a  novel  interaction  between  the 
Hageman factor and complement systems which may have biological relevance. 
Materials and Methods 
Purified Proteins  from Rabbit Plasma 
HAGEMAN FACTOR (HF).I  HF and the two-chain, 80,000-M, form of activated HF (wHFa) 
were purified from rabbit plasma (Fig.  1). 2 
PREV~LLIKREIN (PK).  PK was purified from citrated rabbit  plasma in collaboration with 
Dr. William McGuire of the Research Institute of Scripps Clinic, La Jolla, Calif., by a three- 
step procedure. 
Step I.  Solid-Phase Immunoabsorption of PK  from Rabbit Plasma.  An IgG fraction ofmonospecific 
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Fro.  I.  Proteins purified from rabbit plasma (used in these studies) analyzed by SDS-PAGE  in the 
presence (R) and absence (NR) of ~-mercaptoethanol. Zymogen HF is a single polypeptide chain 
of 82,000 M,. HFa (enzyme) is dissociated into fragments of 52,000 and 28,000 M, in the presence 
of reducing agents. Residual native HF remains at 82,000 M~ in the presence of reducing agents. 
PK zymogen is a single polypeptide chain of 85,000 M,. Upon activation to kallikrein, the single 
polypeptide chain is cleaved into fragments of 55,000 and 35,000 Mr. High-M~  kininogen is a single 
polypeptide chain of 100,000 Mr in the presence and absence of reducing agents. Rabbit C5 is a 
two-chain disulfide-linked molecule of unreduced  180,000 Mr, which dissociates into chains of 
130,000 and 85,000 Mr in the presence  of reducing agent. HF, PK and high-Mr kininogen are shown 
here on 7.5% SDS gels, whereas C5 is shown as a 5% SDS gel. 
goat-anti-rabbit PK was prepared by: (a) absorption of plasma with kaolin (25 mg kaolin/ml) 
incubated for 10 rain at 37°C and then centrifuged for 15 rain at 5,000 g to remove the kaolin; 
(b) dialysis of the kaolin-absorbed serum against 0.01 M phosphate buffer, pH 7.7, followed by 
absorption in batches using DEAE-cellulose (10 g/g protein) equilibrated in the above buffer; 
(c) concentration of the globulin fraction by precipitation with 50% ammonium sulfate and 
subsequent dialysis against 0.1 M  phosphate buffer, pH 7.5. The IgG fraction thus produced 
contained no detectable goat kallikrein (<20 ng/ml), as measured by the chromogenic tripeptide 
assay. 
This IgG fraction in 0.1  M  phosphate buffer, pH  7.5, was coupled to cyanogen bromide- 
activated Sepharose-4B  (5)  at a  ratio of 5 mg of protein/1 g of Sepharose-4B.  The washed 
beads were incubated overnight at +4°C with 5 mM diisopropyi fluorophosphate in water. 
The beads were rewashed and poured into a 2.5- X 30-cm plastic column to a bed height of 26 
cm.  The column was washed with 5 M  guanidine, followed by 0.1  M  Tris buffer, pH  7.4, 
containing 1 M  NaCI, 20 mM EDTA, 10 mM benzamidine, 0.05% hexadimethrene bromide 
(Polybrene; Aldrich Chemical Co., Inc., Milwaukee, Wis.) and 0.02% sodium azide. 
Citrated normal rabbit plasma (200 ml) was made 10 mM with benzamidine, 0.7 M  with 
NaCI, 20 mM EDTA, 0.05% Polybrene, and 0.02% sodium azide. The plasma was run through 
the column at room temperature at a flow rate of 100 ml/h~ The column was washed with 10- 
column volumes of starting buffer and then eluted with 5 M guanidine (Sigma Chemical Co., 
St. Louis, Mo.). The fractions calculated to contain the initial guanidine step and one-column 
volume thereafter were pooled for the second step. 
Step 2.  Ion-Exchange  Chromatography  on SP-Sephadex  C-50.  The pool from Step 1 (200 ml) was 
dialyzed against 0.1 M acetate buffer, pH 5.3, containing 0.04 M NaCl, 2 mM EDTA, 1 mM 
benzamidine, 0.05% Polybrene, and 0.02% sodium azide. 2 g of SP-Sephadex C50 (Pharmacia 
Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.)  hydrated overnight in the above 
buffer was poured into a siliconized 2.5- X 30-cm column. After two changes of dialysis, the 
pool was loaded at 40 ml/h. The column was washed with four-column volumes of starting 
buffer. A step elution was effected with 0.1 M acetate buffer, pH 5.3, containing  0.35 M NaC1 
(= 40 mS). 
Step 3.  Affinity  Chromatography  on  Concanavalin  A-Sepharose.  The pooled fractions containing 
PK (40 ml) were dialyzed against 0.1  M  sodium phosphate buffer, pH  7.5, containing 1 M 
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ml/h  onto  a  1.7-cm  diameter siliconized glass column  containing 6  ml  of concanavalin-A 
Sepharose. The column was washed with 60 mi of the above buffer. Elution of PK was effected 
with the above buffer containing 0.5 M  a-D-methyl glucoside at 2 ml/h. Analysis of the eluted 
protein from the above column by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) under both reducing and nonreducing conditions showed a single protein band 
with a molecular weight (Mr) of 83,000  (Fi~. 1). Assays of PK were performed by immunodif- 
fusion, using goat anti-rabbit PK antiserum. 
KALLXKREIN OENrRATIO~.  Kallikrein wa:~ generated by incubating PK with a-HFa in the 
following manner. PK (1 ml, 220 #g) was incubated with a-HFa (50 #l, 10 #g) in the presence 
of 10 #1  2 M  Tris buffer, pH 8.0, for 60 min at 37°C.  The HFa was not removed from the 
kallikrein preparation, but constituted <1% of the protein present. The extent of proteolytic 
cleavage of prekallikrein as measured by SDS-PAGE (Fig. 1) varied between 58 and 94%  in 
different preparations. The enzymatic activity of kallikrein in each preparation was measured 
colorimetrically  using the tripeptide suhstrate N-Benzoyl-L-Pro-l:phe-L-arginine-p-nitroanalide 
(Bz-pro-phe-arg-pNA; Vega Biochemicals, Tucson, Ariz.) under the conditions described below. 
The calculated I~,t value obtained for  different preparations varied between  300  and  400 
rain  -I. The PK purified in this manner showed a  line of identity with rabbit PK purified by 
ion-exchange chromatography  (6)  and  generously donated by Dr.  Richard  Ulevitch of the 
Research Institute of Scripps Clinic. 
HIOH-Mr KmINOOEN.  High-Mr kininogen was purified from rabbit plasma by a  three-step 
procedure. 
Step I.  Solid-Phase Immunoabsorption of High-Mr Kininogen from Rabbit Plasma.  Goat anti- 
rabbit high-Mr kininogen was coupled to Sepharose 4B as described for PK. Citrated normal 
rabbit plasma was passed over an anti-high-Mr kininogen-Sepharose 4B column and eluted 
with 5 M  guanidine as described above. 
Step 2.  DEAE-Sephadex A50 Ion-Exchange Chromatography.  The pool from Step 1 (500 ml) was 
dialyzed against buffer containing 0.4 M  Tris, 0.1 M  succinic acid, pH 8.2, containing 40 mM 
NaCI, 10 mM benzamidine, 2 mM EDTA, and 0.02% sodium azide. This material was loaded 
onto a 2.5- ×  30-era siliconized column containing 3 g of DEAE-Sephadex AS0 equilibrated in 
the starting buffer. The column was washed with five-column volumes of starting buffer and 
eluted with a gradient consisting of 150 ml of the starting buffer in the proximal chamber and 
150 ml of 0.3 M  Tris, 0.12 M  suecinic acid, pH 7.4, containing 0.3 M  NaCI, 2 mM EDTA,  10 
mM benzamidine, and 0.02% sodium azide. The high-Mr kininogen eluted in the distal shoulder 
of the protein peak, whereas low-M, kininogen eluted in the proximal shoulder of the peak. 
Step 3.  SP-Sephadex Ion-Exchange Chromatography.  The  pool  containing high-Mr  kininogen 
from Step 2  (70 ml) was dialyzed against 0.1  M  acetate buffer, pH 5.3,  containing 75 mM 
NaCI, 10 mM benzamidine, 2 mM EDTA, and 0.02% sodium azide. This material was loaded 
onto 2 g SP-Sephadex C50 equilibrated in the above buffer. The column was washed with 10- 
column  volumes of the above buffer with  the NaCI  increased to 60  mM,  and  the high-Mr 
kininogen was then eluted with a salt gradient to 0.4 M  NaCI in 0.1 M  acetate buffer, pH 5.3. 
The eluted material analyzed by SDS-PAGE in the presence and absence of reducing agents 
revealed a single predominant protein band with an Mr of 100,000  (Fig. 1). This material had 
a  specific clotting activity of 6.5 clotting U/rag, where  1 U  is the amount of rabbit high-Mr 
kininogen  present  in  1 ml  of plasma when  assayed in  human  high-Mr kininogen-deficient 
(Fitzgerald) plasma. 
C5.  C5 was purified from normal rabbit plasma by euglobulin precipitation (pH 5.0), and 
ion-exchange and gel-filtration chromatography as previously described (7).  Rabbit C5 thus 
prepared  was  homogeneous  on  SDS-PAGE  (Fig.  1)  and  contained  no  detectable  C3  by 
functiona_~l or immunoehemical analysis. 
EAC423 Preparation.  Sheep erythrocytes bearing the classical pathway C5 eonvertase were 
prepared from human complement components by the method of Rapp and Borsos (8). 
Chromogenic Tripeptide Assay.  The  synthetic  ehromogenic  tripeptide Bz-pro-phe-arg-pNA 
HC1 was dissolved in 0.1  M  Tris, pH 8.3, containing 0.05 NaCI and 0.02%  sodium azide at a 
final concentration of 0.1  mg/ml. The sample to be assayed (2-5 #1)  was added to a  300-/LI 
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values for K~at were calculated using a  molar extinction coefficient of 10,000  M -x cm  -~ at 405 
nM. 
Neutrophil Function  Assays.  These were performed using leukocytes isolated from New Zealand 
White rabbits as previously described (9). The modified Boyden assay was performed using the 
two-filter technique of Keller et al. (10). The leading front method was performed according to 
Zigmond  and  Hirsch  (11).  Each  sample  was  measured  in  triplicate  and  the  results  were 
expressed as the mean :t:  1 SD from the mean. For each assay positive (5% zymosan-activated 
rabbit  serum  [ZARS]  and  negative  (Hanks'  balanced  salt  solution-bovine  serum  albumin 
[HBSS-BSA])  controls  were  incorporated.  The  Keller  assay  and  leading  front  assays  were 
sensitive to 5 ng and 0.2 ng of human G5a, respectively (9). 
Kinin Bioassay.  This was performed using the estrogen-sensitized rat  uterus assay as previ- 
ously described  (12). 
SDS-PAGE.  Analysis by SDS-PAGE was performed using cylindrical gels and the Weber- 
Osborne system (13). Gels were stained for protein with Goomassie Blue dye or cut into 1.2-ram 
slices and counted for 1~nI on an automated T-counter (Searle Radiographics, Inc., Des Plaines, 
Ill.). 
Miscellaneous.  Protein determinations  were performed by the method of Lowry et al.  (14) 
using BSA (5 times recrystallized; Reheis Chemical Co., Chicago, Ill.) as a standard.  Radiola- 
beling was performed with 125I using the chioramine T  method (15). Neutrophil enzyme release 
was measured as described in reference 16. 
Results 
Chemotactic Activity  Generated from  C5  by  Plasma  Kallikrem.  When  rabbit  C5  was 
incubated  with  rabbit  plasma  kallikrein,  chemotactic  activity could  easily  be  dem- 
onstrated  (Table I). In contrast,  no chemotactic activity could be demonstrated  when 
the zymogen PK was tested with C5 under identical conditions.  Chemotactic  activity 
was also generated when  rabbit  C5 was incubated  with a-HFa,  trypsin,  (Table I), or 
EAC423.  No  chemotaetic  activity  was  produced  when  C5  was  absent  from  the 
incubation  mixtures, or when intact C5 alone was assayed. 
Direct  Chemotactic Effect  of Plasma  Kallikrein.  Because  plasma  kallikrein  has  been 
reported  to be directly chemotactic for neutrophils  (4), we investigated  the ability of 
rabbit  plasma  kallikrein  alone  to  attract  rabbit  neutrophils.  As  shown  in  Table  II, 
over  a  dose-range  from  2.5  ×  10-7-10 -l°  M  kallikrein,  no  detectable  chemotactic 
TABLE  I 
Reagent 
Chemotactic activity (celIs/HPF* ±  1 SD) 
No C5  Added C5 
Buffer  2.4 ±  2.2  2.0 ±  0.9 
Kallikrein  0.6 ± 0.4  50.1 +  3.8 
PK  0.2 ±  0.3  1.8 ±  0.4 
a-HFa  1.5 ±  2.3  25.8 ±  7.7 
Trypsin  1.5 ±  1.2  20.4 ±  1.5 
EAC423  3.0 :k 0.9  18.2 ±  2.4 
ZARS  87.8 ±  23.6  -- 
Chemotactic activit~as generated when kallikrein (1.4 pg), a-HFa (2.4/~g), trypsin 
(0.2/zg),  and EAC423 cells (1  x  107) were incubated with C5 (10 gg). All incuba- 
tions were for 20 min at 37°C with the exception of trypsin,  which was for 2 min at 
22°C. The reaction was stopped with SBTI (40 pg) added for 5 min at 22°C. ZARS 
(5%) was used as a positive control. Each assay was performed in triplicate. 
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TABLE II 
Effect of Plasma Kallikrein upon Neutrophil Chemotaxis 
Plasma  Boyden chamber  Leading front 
kallikrein  (celIs/HPF* 3= 1 SD)  (distance 4-  I SD) 
M 
2.5 ×  10  -7  1.6 +  1.2  14.3 4- 0.6 
10  -7  3.2  4- 2.0 
2.5 ×  10  -8  0.7 4- 0.1  23.0 4- 4.6 
10  -8  0.6 4- 0.2 
2.5 ×  10  -8  1.5 4.  1.6  26.7 4. 3.8 
10  -9  0.6 "4- 0.6 
2.5 ×  10  -1°  27.7 4. 4.9 
Buffer control  0.8 4. 0.4  29.3 4. 5.1 
5% ZARS  87.8 "4- 4.0  145.0  4. 20 
Plasma kallikrein at  the above concentrations was tested for chemotactic 
activity in the presence of HBSS containing BSA  (20 mg/ml) by both the 
modified Boyden assay and the leading front method (n =  3). 
* High power field. 
activity was observed using the modified Boyden chamber (see Materials and Meth- 
ods). This was found consistently in four experiments using two different kallikrein 
preparations. Furthermore, using the more sensitive leading front method (see Mate- 
rials and  Methods), again,  no chemotactic activity could be detected (Table II)  in 
two experiments. 
Enzymatic Activity of the Rabbit Plasma Kallikrein 
To confirm that  the kallikrein used in these experiments was biologically active, 
the following assays were performed. 
TRIPEm'm~. HYDROLYSIS.  The rate of hydrolysis of the synthetic substrate Bz-pro- 
phe-arg-pNA was measured spectrophotometrically. The calculated K~t value ranged 
from 300 to 460 rain  -x under the conditions of assay (see Materials and Methods). 
PROTEOLe'rlc CLEAVAGe  OF m',DIOLAneLED  SUSSTRATeS.  The ability of the kallikrein 
to cleave its natural  substrates,  HF and  high-Mr kininogen, was measured,  x25I-HF 
(200 #g,  0.2 #Ci)  or a25I high-Mr kininogen  (250 #g,  0.2 #Ci)  were incubated with 
dilutions of kallikrein and PK in the presence of 0.1  M  Tris, pH 7.4, and BSA (1 mg/ 
ml). Typical cleavage patterns are shown in Fig.  2, where 12SI-HF was cleaved into 
fragments of 28,000 and 50,000 Mr, and  12sI high-Mr kininogen was cleaved to one 
major fragment containing 12hi with an Mr of 70,000. 
KINtN OEN~TmN.  The ability of kallikrein  to release biologically active kinin 
from rabbit high-Mr-kininogen was measured using an estrogen-sensitized rat uterus 
bioassay system (Table III). 
As confirmed by these studies, the kallikrein was capable of releasing biologically 
active kinin  from high-Mr kininogen in association with proteolytic cleavage of the 
molecule. In  contrast, PK did not  cleave high-Mr kininogen and  did not  generate 
kinin.  However,  if a-HFa  was  incubated  with  PK,  the  PK  was  activated  with 
subsequent release of kinin from high-Mr kininogen. We conclude that all the proteins 
used  in  these  studies  were  capable  of biological  activity  and  that  the  kallikrein 
preparation was indeed kallikrein. 
Chemotactic Effect of HF and High-Mr Kininogen.  Because kallikrein appeared not to 1396  CHEMOTACTIC  ACTIVITY  GENERATED  BY  PLASMA KALLIKREIN 
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FI6.  2.  Radioactivity profiles  from reduced SDS-PAGE of ~25I-HF and  l~I-high-Mr kininogen 
incubated with PK or with kallikrein.  Kallikrein caused proteolytic cleavage of high-Mr kininogen 
into a  major 125I-containing fragment of 70,000 M,.  Kallikrein caused cleavage of I~I-HF into 
fragments of 52,000 and 28,000 Mr. 
TABLE  III 
Kinin Generation by Purified Components of the Rabbit HF System 
Kallikrein  PK  a-HFa  High-Mr  Response  Bradykinin 
kininogen  time  equivalents 
0.9 #g  0.91~g  1.8 #g  71zg  s  ng 
+  --  -  +  3.0  38.0 
-  +  -  +  NR  <4 
-  -  +  +  NR  <4 
-  +  +  +  3.5  30.4 
+  -  -  -  NR  <4 
--  +  +  -  NR  <4 
Purified proteins of the rabbit HF system were incubated together for 10 min at 37°C 
in the presence of 0.05 M Tris buffer containing BSA (1 mg/ml) in a total volume of 
80/~1. 100/~1 of hot (100°C)  saline was added to each tube and the samples were 
boiled for 4 min before the assay using an isolated estrogen-sensitized  rat uterus (see 
Materials and Methods). NR, no response. 
have any chemotactic activity, the natural kallikrein substrates in their activated form 
(a-HFa  and kinin-free high-Mr kininogen) were tested for their ability to attract cells. 
a-HFa,  the  two-chain, 80,000-Mr  form  of activated  HF,  was  tested  over  a dose WIGGINS,  GICLAS,  AND  HENSON  1397 
range  of 7  ×  10-7-7  ×  10  -t°  M  using  the  Boyden assay  system.  No  chemotactic 
activity was observed (data not shown). 
Rabbit high-Mr kininogen (220 #g) was preincubated with rabbit kallikrein (20 #g) 
for 30 min at 37°C  in the presence of 0.1  M  Tris, pH  7.4.  No chemotactic activity 
could be detected in this incubation mixture over a  dose range of 2.5 ×  10-7-2.5 X 
10  -x° M  high-Mr kininogen (data not shown). 
We conclude that neither kallikrein nor HFa nor high-Mr kininogen is capable of 
attracting rabbit neutrophils under the conditions of study. 
Finally, PK (40 #g/ml), HF (22 #g/ml), a-HFa (3 #g/ml), and high-Mr kininogen 
(55 #g/ml)  were incubated together for 20 min at 37°C  in the presence of BSA (1 
mg/ml). Activation of protein was confirmed by measurement of kinin generation by 
bioassay. No chemotactic activity could be demonstrated using the Boyden method. 
We conclude that no detectable chemotactic fragments were generated during acti- 
vation of these proteins. 
Dose-Response Curve of Generation of Chemotactic Activity from C5 by Kallikrein.  A dose- 
response  curve  of rabbit  plasma  kallikrein  incubated  with  rabbit  C5  (at  a  final 
concentration of 100 #g/ml) demonstrated the production of chemotactic activity by 
kallikrein down to a level of ~ 1 #g/ml (Fig. 3) (the physiological concentration of PK 
in rabbit plasmas is ~25 #g/ml). Thus, plasma kallikrein at physiological concentra- 
tion appears to be capable of generating chemotactic activity from C5. 
As  indicated in Table I, a-HFa  also  generated chemotactic activity from C5.  A 
dose-response curve for a-HFa indicated that a-HFa was about one-third as active as 
kallikrein in this respect. 
Kallikrein-blocking Studies.  To establish whether the kallikrein effect on C5 could be 
due to a contaminating enzyme, blocking studies were performed with anti-kallikrein 
IgG and  with  soybean trypsin inhibitor  (SBTI). Rabbit  kallikrein  (20 #g/ml)  was 
incubated with anti-PK or anti-HF antisera at a  final concentration of 8 mg/ml for 
20  min  at  22°C  in  the  presence  of 0.1  M  Tris  buffer,  pH  7.4.  The  kallikrein 
preparations were then assessed for their ability to (a) hydrolyse Bz-pro-phe-arg-pNA; 
(b)  generate kinin  from purified high-Mr kininogen as measured by the rat  uterus 
bioassay; and  (c) generate chemotactic activity from C5. For each assay system, the 
amount of the kallikrein-anti-HF preparation (control) used was on the upper portion 
of the dose-response curve. The response of the kallikrein-anti-PK preparation was 
Ceils 4(] 
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FIG.  3.  Dose-response curve for kallikrein-induced chemotaxis in the presence of C5 (10 #g). The 
final incubation volume was  100/.tl in the presence of 0.05 M  Tris, pH  7.6, containing 0.5 mg/ml 
ovalbumin. After incubation for 20 min at 37°C, SBTI (40 #g) was added for 5 min at 22°C before 
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compared with this value and expressed as the percent of the control. As shown in 
Fig.  4,  the  anti-PK  IgG blocked  the  tripeptide  hydrolysis response  by only 26%, 
whereas the chemotaxis and kinin generation responses were blocked by 41 and 68%, 
respectively. This difference in blocking effect by antibody was reproducible and was 
not effected by changing the ratio of kallikrein to anti-PK. It probably reflects greater 
steric hindrance by the anti-PK IgG-kallikrein complex for the larger substrates and 
possibly the requirement for two clips to liberate kinin from kininogen. 
Kallikrein (5 #g) was also incubated with various doses of STBI (2.9,  1.5, and 0.7 
#g) to generate inactive SBTI-kallikrein complexes in varying proportions such that 
~xA, ½,  and  a~  of the  kallikrein  molecules  would  remain  active.  These  partially 
inhibited kallikrein preparations were compared with a noninhibited control for their 
ability to (a)  hydrolyse the tripeptide Bz-pro-phe-arg-pNA;  (b)  generate bradykinin 
from purified high-Mr kininogen; and (c)  generate a chemotactic response from C5. 
As shown in Fig. 5, the ability of SBTI to inhibit kallikrein activity on three different 
substrates was similar, indicating that the kallikrein-induced chemotactic response 
was due to kallikrein itself and not due to a contaminating enzyme. 
Nature of the Chemotactic Substance Generated  from C5 by Kallikrein 
SECRETION  OF  •-GLUCURONIDASE  FROM  NEUTROPHILS.  C5a  is  capable  of causing 
specific release of granular contents from cytochalasin B-treated neutrophils (9). To 
determine whether kallikrein-treated C5  generated a  fragment capable  of causing 
specific release as well as chemotaxis, the following experiment was performed. 
Isolated rabbit neutrophils were suspended in HBSS in the presence of BSA (0.25%). 
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Aliquots containing 4  X  l06  neutrophils were  incubated  for 5  min  at  37°C  with 
cytochalasin B (5/lg/ml prepared at 5 mg/ml in dimethyl sulfoxide). The cells were 
then exposed to C5 (25 #g), which had been preincubated for 120 min at 37°C either 
with buffer, kallikrein (550  ng), EAC423  (5  ×  107 cells), or trypsin  (300  ng), after 
which SBTI (1 #g) was added to each incubation mixture and allowed to stand for 5 
min at 22°C. Purified human C5a (15 ng) (generously donated by Robert O. Webster, 
National Jewish Hospital and Research Center, Denver, Colo.) was used as a positive 
control. The release of a  granular enzyme,/~-glucuronidase, and a  cytosol enzyme, 
lactic dehydrogenase (LDH), was measured as previously described (16,  17) after 30 
rain incubation with the stimulus. No significant release of LDH occurred  (<5% of 
total releasable by detergent), indicating that no cell lysis had occurred. The base-line 
release of~8-glucuronidase with C5 alone after 120 rain at 37°C was 9.8% of the total 
enzyme releasable by detergent lysis from an equivalent number of cells. In contrast, 
incubation of C5 with kallikrein, EACA23  cells or trypsin resulted in 45.3, 51.4,  and 
49.4% ~8-glucuronidase release, respectively. Purified human C5a caused 53.4% release. 
Thus  kallikrein,  like  EAC423  cells  and  trypsin,  generated  from  C5  a  factor that 
caused rabbit neutrophils to release a specific granular enzyme. 
EFFECT OF  CARBOXYPEPTIDASE N.  Carboxypeptidase  N  cleaves  the  C-terminal 
arginine from human C5a to generate C5a des arg, a molecular species with 100-fold 
less secretogogue activity than C5a (9). To determine whether the chemotactic factor 
generated from C5 by plasma kallikrein was susceptible to carboxypeptidase N, the 
following experiment was performed.  Kallikrein or trypsin was incubated with C5 
under the conditions described above. Human C5a and the rabbit C5-kallikrein and 
C5-trypsin incubates were treated for 5 min at 22°C with  1 mg SBTI to inhibit the 
enzymes and then incubated with or without carboxypeptidase N  (endopeptidase- 
free; Worthington Biochemical Corp., Freehold, N. J.),  1% carboxypeptidase N  (wt/ 
wt) in 1% NaHCO3, pH 7.0, for 15 min at 37°C. The ability of human C5a and the 
C5-kallikrein and C5-trypsin incubates to release fl-glucuronidase in the absence of 
carboxypeptidase N  were 64, 61, and 60% of the total detergent-releasable enzyme, 
respectively. After incubation with carboxypeptidase N, the respective values were 18, 
25, and  16%. Thus, carboxypeptidase N  partially inhibited the specific release of fl- 
glucuronidase from neutrophils by the kallikrein C5 incubate. Furthermore, the extent 
of inhibition was similar to that seen for carboxypeptidase-treated human C5a. 
CLEAVAGE  FRAGMENTS OF C5 GENERATED  BY KALLIKREIN.  Studies were performed to 
determine  the  size  of cleavage  fragments  generated  from C5  by  incubation with 
kallikrein.  Fragments of C5  were visualized by both Coomassie Blue staining and 
autoradiography of 125I-C5 before and after incubation with kallikrein. Analysis of 
the cleaved proteins in the presence and absence of reducing agents was performed on 
exponential gradient (8-20%)  acrylamide gels in the presence of SDS. In the absence 
of reducing agents, a  single cleavage fragment was consistently seen by autoradiog- 
raphy with an apparent  molecular weight of ~14,000.  In the presence of reducing 
agents, only the a-chain of rabbit C5 appeared to be cleaved when analysed both by 
autoradiography and stained gels. In the presence of reducing agents, fragments were 
observed with apparent molecular weights of 50,000,  34,000, and 25,000 in addition 
to the 14,000-Mr  fragment. 
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from C5  and that  the C5  molecule may also be cleaved by kallikrein at additional 
sites.  The 14,000-Mr fragment could be a chemotactic C5a-like molecule. 
Generation of Chemotactic Activity  in  Kaolin-activated  Plasma.  Addition  of kaolin  to 
plasma results in activation of the HF system with consequent kallikrein activation. 
Previous studies  have reported both  that  chemotactic activity is  (4)  or is not  (18) 
generated  during  kaolin  activation  of plasma.  To resolve this  discrepancy,  rabbit 
plasma (containing 0.38% sodium citrate) was activated with kaolin (10 mg/ml final 
concentration,  10-min incubation at 37°C)  under conditions that activate >70% of 
PK to kallikrein. As a  negative control, citrated plasma was used, and as a  positive 
control, citrated plasma was activated with zymosan. Each plasma was assayed for 
chemotactic activity in triplicate. The results are shown in Table IV. Although there 
was  a  consistent  trend  for  kaolin-activated  plasma  to  contain  more  chemotactic 
activity than control plasma, this was only statistically significant when low concen- 
trations of plasma were used. These results and other studies consistently indicated 
that kaolin-activated plasma tends to contain more chemotactic activity than control 
plasma but much less chemotactic activity than zymosan-activated plasma. However, 
when kaolin was added to zymosan-activated rabbit plasma at a  final concentration 
of 50 mg/ml, the chemotactic activity was reduced from 58.7 :t:  10.3 to 3.5 zt: 1.6 (n 
--  3, P  <  0.01).  Thus, at  high concentrations kaolin blocks detectable chemotactic 
activity, probably by binding positively charged C5a to the negatively charged kaolin 
surface. 
Therefore,  although  the  assessment  of chemotactic  activity  in  kaolin-activated 
plasma  is  complicated by the probable binding  of C5a  to kaolin,  the chemotactic 
activity of plasma did appear to increase after incubation with kaolin. 
Discussion 
Previous studies using partially purified preparations of human plasma kallikrein 
have indicated that kallikrein itself might be directly chemotactic for neutrophils (4, 
19-21).  This observation is  surprising,  because no other enzyme is  known  to have 
direct chemotactic activity. In particular, trypsin, with its ability to hydrolyse peptide 
TABLE IV 
Chemotactic Activity in CeUs/HPF* 
Plasma con-  Control plasma,  Kaolin-activated  Zymosan-activated 
centration  plasma, (mean ±  1  plasma, (mean ±  1 
used  (mean +  1 SD)  SD)  SD) 
% 
0.5  3.2  1.8  5.5  0.1~  71.3  38.2~: 
1.0  3.1  1.5  4.9  0.8  77.4  20.9{} 
5.0  4.5  2.4  8.4  2.2  107.6  25.9{} 
10.0  5.0  1.6  5.6  1.7  103.1  21.6{} 
Chemotactic activity present in plasmas after incubation alone or with kaolin  (5 
mg/ml) or  zymosan (5  mg/ml)  for  10  rain  at  37°C.  Each sample was  tested  in 
triplicate as described in Materials and Methods. Section marks indicate indicate 
the degree of significance between the treated and control plasmas as indicated by 
a  paired t test. 
* High power field. 
1: P < 0.05. 
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bonds adjacent to positively charged residues in a  rather unrestricted fashion, is not 
itself chemotactic. This contrasts with the fact that the trypsinlike arginine esterase 
plasma kallikrein appeared to require enzymatic activity for its chemotactic activity 
(4). 
The findings from this study, using highly purified and well characterized proteins 
and cells of rabbit origin, indicate that rabbit plasma kallikrein is not chemotactic. In 
addition, HF, HFa, high-Mr kininogen, activated high-Mr kininogen, and PK were 
not chemotactic alone or when incubated together so that activation occurred in the 
incubation mixture. Thus, activation of the purified proteins of the HF system did 
not  generate  a  chemotactic  fragment  that  was  detectable  under  the  conditions 
employed in this study. 
However, plasma  kallikrein was capable of producing a  chemotactic effect if C5 
was included in the incubation mixture. Plasma kallikrein at concentrations as low as 
1 #g/ml appeared to be capable of generating a chemotactic effect from C5 when the 
latter was present at physiological concentrations (100 #g/ml). It is unlikely that this 
effect was  due to a  contaminating protease that  was  not  detected in the kallikrein 
preparation  by  SDS  or  alkaline  gel  analysis,  because  specific anti-kallikrein  IgG 
inhibited kallikrein-mediated kinin generation and kallikrein-mediated chemotaxis ~o 
a  similar extent. The finding that  the antibody only partially inhibited both effects 
provides stronger evidence that  the same enzyme was involved. Furthermore, SBTI 
also inhibited the kinin-generating, chemotactic, and tripeptide-hydrolysing effects to 
the same extent. We conclude that the chemotaxis generation was due to the action 
of plasma kallikrein on C5. 
The nature of the chemotactic substance generated from C5 by kallikrein appeared 
to be similar to C5a. Thus, it was chemotactic, it stimulated fl-glucuronidase release 
from  cytochalasin  B-treated  neutrophils,  it  was  sensitive  to  carboxypeptidase  N 
digestion, and its activity was associated with the generation of a  low-Mr fragment 
(-14,000) from C5. In addition, the amount ofchemotactic and secretagogue activity 
generated from C5  by kallikrein was consistent with calculations of the amount of 
C5a activity that could be released from the quantity of C5 in the initial incubation 
mixture.  Furthermore,  kallikrein,  like  trypsin,  is  an  arginine  esterase  and  the  C- 
terminal amino acid of both human and porcine C5a is arginine (22). From the above 
considerations, it seems likely that  C5a can be released from rabbit  C5  by plasma 
kallikrein. 
The potential importance of kallikrein in liberating CSa from C5 in vivo is not yet 
known. However, during tissue injury, substances such as bacterial lipopolysaccharides 
(23), collagen and elastin (24-26), basement membrane (27), and sodium urate and 
pyrophosphate  crystals  (28)  may  act  as  negatively  charged  surfaces  upon  which 
assembly and activation of the molecules of the HF system can occur (29). Damaged 
endothelial cells contain an enzyme capable of directly activating HF  (12). Under 
these conditions, kallikrein could be generated that might then release C5a from C5. 
The  importance of the  capacity of C5a  to  bind  to negatively charged  substances, 
thereby creating a stable surface-bound gradient for orientation of migrating neutro- 
phils, has previously been emphasized (30). Thus, it is not surprising that negatively 
charged  agents,  such  as  kaolin,  used  to activate the  HF system  in  the laboratory, 
should also have the capacity to bind C5a. Although this fact makes the measurement 
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may  reflect  the  importance  of exposure  of negatively  charged  substances  such  as 
basement membrane, collagen, or elastin during tissue injury. It is possible that these 
negatively charged substances may not only allow activation of the HF system with 
kallikrein  generation,  but  may also  bind  C5a  locally generated  by kallikrein  with 
consequent effects on vascular permeability and attraction of two major effector cells 
of inflammation: neutrophils and macrophages (31-34). 
There  remains  the  apparent  discrepancy  between  the  findings  described  in  this 
study using rabbit proteins and previous observations using human proteins  (4,  19- 
21).  One possible explanation  for this discrepancy would be that human leukocytes 
have a  membrane-associated C5-9 complex (35).  Human kallikrein might therefore 
release  C5a  from  membrane-bound  C5  and  thus  appear  to  be chemotactic  in  the 
assay system.  It is possible that  the concentrations  of rabbit  kallikrein  used  in  this 
study were not sufficient to observe this effect with rabbit leukocytes. 
Summary 
Rabbit  plasma kallikrein  incubated with rabbit  C5 resulted  in the generation  of 
chemotactic  and  secretagogue  activity  for  rabbit  neutrophils.  This  effect  on  C5 
appeared to be due to kallikrein itself and not to a contaminating enzyme, because it 
could be inhibited by anti-kallikrein IgG or by soybean trypsin inhibitor to the same 
extent that kinin generation by the same kallikrein preparation was inhibited by these 
agents.  The chemotactic response was consistent  with  the generation  of a  C5a-like 
peptide from C5 because the effect could be partially inhibited by carboxypeptidase 
N  and was related to the generation of a small (~ 14,000 mol wt) fragment of C5. 
No direct chemotactic response was detectable for kallikrein, activated Hageman 
factor, high-molecular weight kininogen, or intact C5. Incubation of kallikrein, high- 
molecular weight kininogen,  and Hageman factor together, so that activation of all 
three  proteins  occurred,  did  not  result  in  the  generation  of detectable  chemotactic 
activity. 
We wish to acknowledge the skilled technical performance of the chemotaxis assays by Bettina 
Zanolari and Pamela J. Keeling, and the constructive secretarial help of Betty Goddard. 
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